Immunotherapy for oesophagogastric cancer

Area of Science:

• Oncology
• Gastroenterology
• Immunology

Background:

• Gastric and oesophageal cancers present a significant global health challenge with high mortality.
• Current palliative treatments, primarily chemotherapy, offer limited survival benefits for advanced disease.
• There is growing interest in utilizing immunotherapy to enhance treatment efficacy for these cancers.

Purpose of the Study:

• To review the aetiological and genetic factors of oesophagogastric (OG) cancers pertinent to immunotherapy.
• To outline the historical, current, and future applications of immunotherapy in OG cancer management.

Main Methods:

• Review of existing literature on OG cancer aetiology, genetics, and immunotherapy applications.
• Analysis of PD1 pathway inhibitors and their efficacy in OG cancer patients.
• Exploration of combinatorial treatment strategies and biomarker identification.

Main Results:

• PD1 pathway inhibitors have shown durable responses in a subset of OG cancer patients.
• Combinatorial approaches involving chemotherapy, radiotherapy, and other agents are expected to improve outcomes.
• Personalized neoantigen-based vaccines, enabled by sequencing technology, show promise.

Conclusions:

• Immunotherapy, particularly PD1 pathway targeting, represents a promising avenue for OG cancer treatment.
• Biomarker identification is critical for refining immunotherapy strategies and patient selection.
• Genomic advancements are paving the way for personalized immunotherapy approaches like neoantigen vaccines.